BMS-986263
BMS-986263 is an experimental "retinoid-conjugated lipid nanoparticle (LNP) containing HSP47 small interfering RNA (siRNA)" intended to block the synthesis of HSP47, "a collagen-specific chaperone protein involved in fibrosis development". The drug is being tested on people with serious hepatic impairment or fibrosis,[1][2] including compensated cirrhosis resulting from nonalcoholic fatty liver disease.[3]
References[edit]
- ^ Qosa, Hisham; de Oliveira, Claudia H. M. C.; Cizza, Giovanni; Lawitz, Eric J.; Colletti, Nicholas; Wetherington, Jeffrey; Charles, Edgar D.; Tirucherai, Giridhar S. (October 2023). "Pharmacokinetics, safety, and tolerability of BMS-986263, a lipid nanoparticle containing HSP47 siRNA, in participants with hepatic impairment". Clinical and Translational Science. 16 (10): 1791–1802. doi:10.1111/cts.13581. PMC 10582666. PMID 37654022.
- ^ Lawitz, Eric J.; Shevell, Diane E.; Tirucherai, Giridhar S.; Du, Shuyan; Chen, Warner; Kavita, Uma; Coste, Angie; Poordad, Fred; Karsdal, Morten; Nielsen, Mette; Goodman, Zachary; Charles, Edgar D. (April 2022). "BMS-986263 in patients with advanced hepatic fibrosis: 36-week results from a randomized, placebo-controlled phase 2 trial". Hepatology. 75 (4): 912–923. doi:10.1002/hep.32181. PMC 9299674. PMID 34605045.
- ^ "CTG Labs - NCBI". clinicaltrials.gov. Retrieved 2 December 2023.